Hematologic Oncology Update
Hematologic Oncology Update
✓

Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies

· Notizen anzeigen
00:47:06
Podcasts
RSS
Link

ÜBER DIESE EPISODE

Featuring an interview with Dr L Elizabeth Budde, including the following topics:

  • Considerations for selecting between bispecific antibodies (BsAbs); monotherapy versus combination therapy (0:00)
  • Management of BsAb-induced cytokine release syndrome and other toxicities (7:35)
  • Use of BsAbs in the front-line treatment of diffuse large B-cell lymphoma (DLBCL); key findings from the Phase II MorningSun study (17:30)
  • Case: A man in his mid 50s with relapsed/refractory (R/R) DLBCL receives mosunetuzumab and polatuzumab vedotin in the second-line setting (23:18)
  • Case: A woman in her early 70s with R/R DLBCL receives glofitamab monotherapy in the third-line setting (32:52)
  • Case: A man in his early 80s with R/R DLBCL experiences disease progression after lisocabtagene maraleucel therapy, which was bridged with epcoritamab and gemcitabine/oxaliplatin (37:35)

CME information and select publications

Wissenschaft
Medizin
Englisch
Vereinigte Staaten
Verwenden SieAPI, um diese Episode inJSONabzurufen

IN DIESER FOLGE

Diese Tags bearbeiten

NOTIZEN ANZEIGEN 🔗

00:00:00Considerations for selecting between bispecific antibodies (BsAbs); monotherapy versus combination therapy
00:07:35Management of BsAb-induced cytokine release syndrome and other toxicities
00:17:30Use of BsAbs in the front-line treatment of diffuse large B-cell lymphoma (DLBCL); key findings from the Phase II MorningSun study
00:23:18Case: A man in his mid 50s with relapsed/refractory (R/R) DLBCL receives mosunetuzumab and polatuzumab vedotin in the second-line setting
00:32:52Case: A woman in her early 70s with R/R DLBCL receives glofitamab monotherapy in the third-line setting
00:37:35Case: A man in his early 80s with R/R DLBCL experiences disease progression after lisocabtagene maraleucel therapy, which was bridged with epcoritamab and gemcitabine/oxaliplatin

TRANSKRIPT 🔗

Are you the producer of this podcast? Add a podcast transcript
Need Audio-to-Text? Transcribe with Listen411 in Just 60 Seconds

VERGANGENE FOLGEN SUCHEN

Vorhandene Folgen von Hematologic Oncology Update durchsuchen.
Betten Sie diese Suchleiste in Ihre Website ein

WEITERE EPISODEN IN DIESEM PODCAST

Myelofibrosis — Proceedings from a Webinar Held in Conjunction with the 2026 ASCO Annual Meeting

Myelofibrosis — Proceedings from a Webinar Held in Conjunction with the 2026 ASCO Annual Meeting

Featuring perspectives from Prof Claire Harrison and Dr Raajit K Rampal, including the following topics: Introduction (0:00) The Biopathophysiology of Myelofibrosis (MF) (2:19) Current and Future Clinical Decision-Making in the Absence of Severe Cytopenias — Prof Harrison (7:49) Managing MF for Pa…
00:57:46
TEILEN
SPEICHERN
Non-Hodgkin Lymphoma — Year in Review Series on Relevant New Datasets and Advances

Non-Hodgkin Lymphoma — Year in Review Series on Relevant New Datasets and Advances

Featuring perspectives from Dr Matthew Matasar and Dr Sonali M Smith, including the following topics: Introduction: Lymphoma Survivorship (0:00) Novel Treatment Approaches for Diffuse Large B-Cell Lymphoma — Dr Matasar (6:49) Novel Treatment Approaches for Follicular Lymphoma and Mantle Cell Lymph…
01:00:04
TEILEN
SPEICHERN
Relapsed/Refractory Chronic Lymphocytic Leukemia — A Grand Rounds Program

Relapsed/Refractory Chronic Lymphocytic Leukemia — A Grand Rounds Program

Featuring perspectives from Dr William G Wierda, including the following topics: Introduction: Overview of the Grand Rounds Chronic Lymphocytic Leukemia Initiative (0:00) Sequencing Road Map (12:39) Key Datasets — Pirtobrutinib (21:08) Investigator Survey (34:09) Chimeric Antigen Receptor T-Cell T…
00:58:40
TEILEN
SPEICHERN
Multiple Myeloma — Year in Review Series on Relevant New Datasets and Advances

Multiple Myeloma — Year in Review Series on Relevant New Datasets and Advances

Featuring perspectives from Dr Amrita Krishnan and Dr Robert Z Orlowski, including the following topics: Introduction (00:00) Up-Front Progression-Free Survival for Standard-Risk Disease — 2006, 2016 (1:47) Current and Emerging Therapeutic Approaches — Dr Orlowski (10:34) Chimeric Antigen Receptor…
00:57:45
TEILEN
SPEICHERN
Non-Hodgkin Lymphoma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting on the Roles of CAR T-Cell Therapy and Bispecific Antibodies

Non-Hodgkin Lymphoma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting on the Roles of CAR T-Cell Therapy and Bispecific Antibodies

Featuring perspectives from Dr Jeremy S Abramson, Dr Joshua Brody, Dr Manali Kamdar, Dr Tycel Phillips and Dr Jason Westin, moderated by Dr Abramson, including the following topics: Introduction (0:00) Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Ka…
01:59:30
TEILEN
SPEICHERN
Rechtliche Hinweise: Der auf dieser Seite eingebettete Podcast und das Bildmaterial stammen von Dr. Neil Love, das Eigentum seines Eigentümers ist und nicht mit Listen Notes, Inc. verbunden ist oder von diesen unterstützt wird.
PROMOTED
Listen411.com: Lightning-fast Podcast Transcription and Summarization. Transcribe 1-hour audio in under 1 minute. Pay-as-you-go.
Listen411.com: Lightning-fast Podcast Transcription and Summarization. Transcribe 1-hour audio in under 1 minute. Pay-as-you-go.
Audio to Text

EMPFEHLUNGEN
API benutzen um diese Episode zu bekommen